{
  "catalysts": [
    {
      "ticker": "HRMY",
      "current_price": 38.27,
      "market_cap": "$3.2B",
      "conviction_score": 7,
      "thesis": "Company pre-announced strong Q4 beat and raised 2026 guidance to >$1B (blockbuster status), confirming growth durability which the market has historically doubted.",
      "catalyst_details": "J.P. Morgan Healthcare Conference Presentation (Jan 13, 2026) and 2026 Guidance Update.",
      "absorption_status": "Unreacted: Stock +0.8% pre-market despite confirming $1B+ revenue trajectory and pipeline expansion.",
      "earnings_date": "2026-02-24",
      "relative_volume": "1.2x (Accumulation)",
      "stop_loss_trigger": "$36.63 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "High confidence in guidance",
      "recency_proof": "BusinessWire Jan 12, 2026: 'Harmony Guides to Over $1 Billion in WAKIX Revenue in 2026...'",
      "risk": "Pipeline execution risks",
      "expected_upside": "+25% (Analyst targets ~$46) | Target: $41.55",
      "mispricing_evidence": "Trading at ~10x forward earnings despite 20%+ growth and blockbuster product confirmation.",
      "x_sentiment": "Quiet Accumulation",
      "atr_value": 1.09,
      "calculated_stop_loss": 36.63,
      "calculated_target": 41.55
    }
  ]
}